Long‐term safety of replication‐defective smallpox vaccine (MVA‐BN) in atopic eczema and allergic rhinitis
Authors:
- 29 June 2016
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (11) , 1971-1977
Abstract
Background: Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara (MVA)‐BN, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile.Methods: A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects. Healthy subjects, subjects with a history of AE, subjects with mild active AE and subjects with mild allergic rhinitis without AE were equally allocated into four groups. MVA‐BN was injected s.c. in a dose of 108 TCID50 twice in a 4‐week interval.Results: No serious or unexpected adverse reactions were reported. All subjects experienced mild to moderate pain and redness at the injection site. Dermatologic examinations did not reveal any unfavourable reactions to the study medication, particularly no sign or exacerbation of eczema for as long as 196 days. All subjects seroconverted after two vaccinations and no significant difference in antibody titres between the four different groups was observed.Conclusions: A good safety profile of the MVA‐BN vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with AE or other atopic diseases.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (N01-AI-30016)
This publication has 14 references indexed in Scilit:
- Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitisVaccine, 2014
- Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitisJournal of Allergy and Clinical Immunology, 2011
- Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammationJournal of Allergy and Clinical Immunology, 2007
- Smallpox vaccines: Past, present, and futureJournal of Allergy and Clinical Immunology, 2006
- Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineVaccine, 2006
- Itch and pruritus: what are they, and how should itches be classified?Dermatologic Therapy, 2005
- Modified Vaccinia Ankara: Potential as an Alternative Smallpox VaccineClinical Infectious Diseases, 2004
- Selective Killing of Vaccinia Virus by LL-37: Implications for Eczema VaccinatumThe Journal of Immunology, 2004
- Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic DermatitisDermatology, 1997
- MVA-Stufenimpfung gegen PockenDMW - Deutsche Medizinische Wochenschrift, 1974